Novartis
NVS
1,272 hedge funds and large institutions have $14.3B invested in Novartis in 2023 Q4 according to their latest regulatory filings, with 140 funds opening new positions, 402 increasing their positions, 447 reducing their positions, and 69 closing their positions.
103% more first-time investments, than exits
New positions opened: 140 | Existing positions closed: 69
4% more funds holding
Funds holding: 1,222 → 1,272 (+50)
7% more call options, than puts
Call options by funds: $229M | Put options by funds: $215M
0.32% less ownership
Funds ownership: 6.52% → 6.2% (-0.32%)
6% less capital invested
Capital invested by funds: $15.1B → $14.3B (-$834M)
10% less repeat investments, than reductions
Existing positions increased: 402 | Existing positions reduced: 447
13% less funds holding in top 10
Funds holding in top 10: 16 → 14 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MIP
Mondrian Investment Partners
London,
United Kingdom
|
+$78.2M |
| 2 |
Goldman Sachs
New York
|
+$73.5M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
+$72.9M |
| 4 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$42.5M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$42.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Charles Schwab
San Francisco,
California
|
-$409M |
| 2 |
Dodge & Cox
San Francisco,
California
|
-$299M |
| 3 |
Primecap Management
Pasadena,
California
|
-$163M |
| 4 |
CCM
Cullen Capital Management
New York
|
-$105M |
| 5 |
Sanders Capital
West Palm Beach,
Florida
|
-$104M |
NVS Hedge Fund Activity: Q4 2023 in Review
1,272 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q4 2023, worth a combined $14.3B — down 5.5% from $15.1B a quarter earlier.
Buyers outnumbered sellers: 140 funds opened new NVS positions and 69 closed out — a net gain of 71 holders — while 402 added to existing stakes and 447 trimmed.
The largest buyer was Mondrian Investment Partners, adding an estimated $78.2M. The largest seller was Charles Schwab, cutting an estimated $409M.
- 1,272 institutional investors held Novartis (NVS) as of Q4 2023, up from 1,222 in Q3 2023.
- Funds reported $14.3B of Novartis stock for Q4 2023, down 5.5% quarter-over-quarter.
- 140 funds opened new Novartis positions in Q4 2023 and 69 closed out, a net change of +71 holders.
- The largest Novartis buyer in Q4 2023 was Mondrian Investment Partners, an estimated $78.2M added.
- The largest Novartis seller in Q4 2023 was Charles Schwab, an estimated $409M sold.
Based on aggregated 13F filings for Q4 2023.